Insmed's lung infection drug succeeds in late-stage trial

July 1 Mon Jul 1, 2013 7:25am EDT

July 1 (Reuters) - Insmed Inc said a late-stage trial of its experimental lung infection drug showed the therapy was as effective as another approved treatment.

The drug, Arikace, was being tested as a treatment for a bacterial infection in cystic fibrosis patients. The trial met its main goal of showing Arikace was not inferior to Tovi, Novartis's drug for the same infection.

We welcome comments that advance the story through relevant opinion, anecdotes, links and data. If you see a comment that you believe is irrelevant or inappropriate, you can flag it to our editors by using the report abuse links. Views expressed in the comments do not represent those of Reuters. For more information on our comment policy, see
Comments (1)
Nighty wrote:

Jul 01, 2013 8:45am EDT  --  Report as abuse
This discussion is now closed. We welcome comments on our articles for a limited period after their publication.